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Studies using T-cell receptor (TCR) or chimeric antigen
receptor (CAR) transduced T-cells have shown the effec-
tiveness of adoptive immunotherapy to treat different
malignancies. The efficacy and safety of such interventions
greatly depends on good target selection to prevent on-
target toxicity. Furthermore, the broad application of
TCR-based adoptive immunotherapy is hampered by a
lack of an effective immune response against self-antigens.
Through self-tolerance, T-cells carrying high-affinity TCRs
reactive to self-antigens are deleted during thymic selec-
tion. An attractive strategy is to exploit the immunogeni-
city of foreign human leukocyte antigen (HLA) molecules
to generate an effective immune response against these
antigens. Here, we describe a protocol to efficiently isolate
high-avidity alloHLA-restricted T-cells targeting the B-cell
compartment.
From a B-cell peptide elution library 15 peptides
derived from genes exhibiting B-cell restricted expression
patterns were identified and peptide-MHC multimers
(pMHC) of HLA-A*0201 were generated. Via MACSort-
ing and FACSorting a plethora of pMHC-multimer bind-
ing T-cell clones from HLA-A*0201-negative individuals
were isolated. Generated T-cell clones were selected
based on peptide-specificity and avidity for further
characterization.
We successfully isolated two distinct T-cell clones carry-
ing high-affinity TCRs specific for a CD20 peptide pre-
sented in HLA-A*0201. CD20 dependent recognition
could be demonstrated by genetically engineering CD20-
negative K562-A2 cells to express CD20. The isolated
T-cell clones efficiently recognized CD20-expressing
HLA-A*0201 primary chronic lymphocytic leukaemia
(CLL), acute lymphoblastic leukaemia (ALL) and mantle
cell lymphoma (MCL), while recognition of CD20-negative
hematopoietic and non-hematopoietic cell-subsets was
absent. In addition, the CD20-specific T-cell clones were
able to more efficiently recognise ALL cell-lines than
CD20 specific antibodies. We demonstrated that on ALL
cell lines with only very low CD20 surface expression, the
CD20-specific T cell clones could still efficiently recognise
endogenously processed CD20-derived peptides in the
context of HLA-A*0201.
In conclusion, we developed a platform for the rapid
identification of high-affinity TCRs of therapeutic rele-
vance targeted to self-antigens by combining gene expres-
sion data with valuable information on peptide processing
from peptide elution studies and exploiting the immuno-
genicity of foreign HLA. Using this platform we success-
fully isolated CD20-specific TCRs which could broaden
the application of immunotherapies targeted to CD20 in
cases were CD20-cell surface expression is low. Based on
its general principle the developed platform could easily
be adapted to target other malignancies.
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